CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical...
Cancer
Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)
Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACS Consistent Improvements in Weight Gain,...
Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
Live moderated webcast on Thursday, September 4th at 4:00 PM ET Access the event here BOSTON and LONDON, Sept. 03,...
Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study
New longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a mean...
Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation
Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA...
Coherus Oncology to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be...
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Media ReleaseCOPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse...
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused...
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies October...
CG Oncology Completes Enrollment in PIVOT-006
– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized...
Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-7625th cohort patients now being treated in...
St. Baldrick’s Foundation Kicks Off Childhood Cancer Awareness Month with New ‘Send Kids’ Cancer Packing’ Initiative
Los Angeles, California--(Newsfile Corp. - September 2, 2025) - Each year, more than 15,000 families in the U.S. hear the...
TOBY Appoints Healthcare Leader Matthew Collier as Independent Director
BOSTON, Sept. 2, 2025 /PRNewswire/ -- TOBY, Inc., a leader in noninvasive multi-cancer early detections, has appointed Matthew Collier to the TOBY...
Olympus Announces U.S. Launch of Newest Imaging Platform for ENT and Urological Applications
VISERA™ S Offers Advanced Diagnostic Imaging Capabilities in a Variety of Patient Settings CENTER VALLEY, Pa., Sept. 2, 2025 /PRNewswire/...
Golden Helix and Genomenon Announce Strategic Partnership to Advance Clinical Diagnostics
BOZEMAN, Mont., Sept. 2, 2025 /PRNewswire/ -- Golden Helix, a global leader in clinical bioinformatics, today announced a strategic partnership with...
Desilo to Launch “HARVEST™,” Encrypted Data Collaboration Platform for Healthcare, in December
SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Desilo Inc., a privacy-technology startup specializing in cryptographic data collaboration, announced plans...
Amorphical Appoints Eden Ben as CEO, as Company Advances Regulatory Pathway for Nano-Amorphous Mineral-Based Therapeutics
Pipeline of Disease-Modifying Therapies Targets Hypoparathyroidism, Pancreatic Cancer, osteoporotic fractures, and Crohn's Disease NES ZIONA, Israel, Sept. 2, 2025 /PRNewswire/ -- Amorphical,...
Abridge Partnership Scales Ambient Clinical Intelligence Across Hartford HealthCare’s Clinical Enterprise
HARTFORD, Conn. & PITTSBURGH--(BUSINESS WIRE)--Abridge’s AI-powered ambient clinical intelligence platform has been selected by Hartford HealthCare, Connecticut’s most comprehensive healthcare...
Predicine Submits First Module of PMA Application to FDA for PredicineCARE™ as a Companion Diagnostic Assay in Bladder Cancer
HAYWARD, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, today announced the submission of...
Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology...